Loss of Wild Type BRCA1 in Breast Cancer
Author Information
Author(s): Tung Nadine, Miron Alexander, Schnitt Stuart J, Gautam Shiva, Fetten Katharina, Kaplan Jennifer, Yassin Yosuf, Buraimoh Ayodele, Kim Ji-Young, Szász Attila M, Tian Ruiyang, Wang Zhigang C, Collins Laura C, Brock Jane, Krag Karen, Legare Robert D, Sgroi Dennis, Ryan Paula D, Silver Daniel P, Garber Judy E, Richardson Andrea L
Primary Institution: Beth Israel Deaconess Medical Center
Hypothesis
The study aims to compare the prevalence of loss of wild type BRCA1 in estrogen receptor positive and negative breast cancers in BRCA1 mutation carriers.
Conclusion
The study found no significant difference in the prevalence of loss of wild type BRCA1 between estrogen receptor positive and negative invasive BRCA1-associated breast cancers.
Supporting Evidence
- 81.0% of ER+ cancers had loss of wild type BRCA1.
- 88.6% of ER- cancers had loss of wild type BRCA1.
- Age at diagnosis was not significantly different between cancers with and without loss of wild type BRCA1.
- ER+ cancers retaining wild type BRCA1 were more likely to have a low mitotic rate.
Takeaway
This study looked at breast cancer in women with a BRCA1 mutation and found that losing a specific gene (BRCA1) happens equally in two types of breast cancer, whether they are hormone-sensitive or not.
Methodology
The study measured BRCA1 DNA in cancer cells from 42 ER+ and 35 ER- breast cancers using quantitative PCR and assessed BRCA1 gene methylation.
Limitations
The study could not determine the status of the wild type BRCA1 allele in 21 cancers due to various technical issues.
Participant Demographics
The study involved women with deleterious BRCA1 germ-line mutations.
Statistical Information
P-Value
0.53
Confidence Interval
95% CI, 1.91 to ∞
Statistical Significance
p=0.53
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website